September 22, 2023
AstraZeneca, Daiichi Sankyo’s Dato-DXd improved PFS in breast cancer
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial.